Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Patrick Hanley

Associate Professor

George Washington University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

About

Patrick Hanley is an Associate Professor at George Washington University, USA. His research focuses on immunotherapy, specifically in the areas of cell and gene therapy, HIV-specific T cell therapy, and the safety and efficacy of tumor-associated antigen-specific T cells. He has contributed to various studies on the application of flow cytometry in therapeutic settings and the manufacturing practices of cellular therapy products.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

George Washington University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Patrick Hanley

Research Interests

Explore related searches

About

Articles (13)

Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study

Review of flow cytometry as a tool for cell and gene therapy

Environmental monitoring of current good manufacturing practices cleanroom facilities for manufacturing of cellular therapy products in an academic hospital setting

Emerging frontiers in immuno- and gene therapy for cancer

Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma

Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience

ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.

Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures.

Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

Influence of administration of mesenchymal stromal cell on pediatric oxygenator performance and inflammatory response.

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.

Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Collaborators (7)

Christopher Lazarski

Michael Keller

John Ligon

Catherine M. Bollard

Alexey Bersenev

Jeremy Rubinstein

Chase McCann

Make your next move.